Adaptimmune Q4 2020 Earnings Report
Key Takeaways
Adaptimmune reported a revenue of $1.5 million and a net loss of $36.6 million for the fourth quarter of 2020. The company's total liquidity was $368.2 million as of December 31, 2020, and it believes that its existing cash, cash equivalents and marketable securities will fund operations into early 2023.
Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers
Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric junction, and melanoma cancers confirming potential of SPEAR T-cells for solid tumors
Completed enrollment of SPEARHEAD-1 clinical trial, to support planned BLA filing and commercialization in 2022 for ADP-A2M4 for people with synovial sarcoma
Initiating Phase 2 trial (SURPASS-2) with ADP-A2M4CD8 in esophageal and esophagogastric junction cancers in 1H 2021
Adaptimmune
Adaptimmune
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into early 2023, as further detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, to be filed with the Securities and Exchange Commission following this earnings release.